Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative
biotechnology company, has set its sights on using its proprietary drug
delivery technology to provide an alternative method of nicotine ingestion that
is safer than smoking. An article further discussing the company reads, “The
technology, known as DehydraTECH(TM), is a patented, cost-effective delivery
mechanism that has been shown to improve the ingestibility of cannabinoids,
vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now,
Lexaria has partnered with one of the world’s largest tobacco firms to develop
new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe). . . . The
deal funds Lexaria’s R&D program — and consumer product development — in exchange
for certain DehydraTECH license rights and a minority equity interest in
Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An
initial tranche of $1 million has been provided, with additional phases
providing up to $12 million total. Lexaria has granted a license for its
technology to be used in nicotine-based, oral-format products on an exclusive
basis in the United States and a nonexclusive basis elsewhere globally, for
which it will receive royalties on every dollar of revenue generated utilizing
its technology.”
To view the full article, visit http://ibn.fm/dvdIc
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in more than 40 countries around the world and has
patents granted in the United States and in Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
